• Recruiting

NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With RRMM

Updated: Sep 22


NCT03275103: Phase 1 - Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)


Cevostamab

A Phase I Study of BFCR4350A in People with Previously Treated Multiple Myeloma


This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).


Sponsor

Genentech, Inc


Multiple locations

International study

 

ClinicalTrials.gov Identifier: NCT03275103

Official Title: An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cevostamab (BFCR4350A) in Patients With Relapsed or Refractory Multiple Myeloma

First Posted : September 7, 2017


Click here for details on ClinicalTrials.gov

 

Cevostamab

 

Drug: Cevostamab

anti-FCRH5 x anti-CD3 bi-specific T-cell engager BFCR4350A

BFCR4350A


Drug: Tocilizumab

 

COMY 22 - Session 15: Abstract communications

AN ONGOING PHASE I STUDY SHOWS CLINICALLY MEANINGFUL ACTIVITY AND MANAGEABLE SAFETY OF CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE]

Click here for details

 

157 Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Program: Oral and Poster Abstracts

Type: Oral

Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid

Hematology Disease Topics & Pathways:

Biological, Bispecific Antibody Therapy, Diseases, Therapies, Lymphoid Malignancies

Saturday, December 11, 2021: 12:00 PM

Click here for details

 

- Alabama: University of Alabama at Birmingham

- Arizona: Mayo Clinic Arizona

- California: University of California San Francisco

- California: City of Hope Duarte

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- Texas: The University of Texas MD Anderson Cancer Center Houston

- Tennessee: Sarah Cannon Research Institute Nashville

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: Memorial Sloan-Kettering Cancer Center New York

- Pennsylvania: University of Pennsylvania Philadelphia

 

Locations

United States, Alabama

United States, Arizona

United States, California

United States, Colorado

United States, Massachusetts

United States, New York

United States, Pennsylvania

United States, Tennessee

United States, Texas

Canada, Alberta

Canada, Ontario

Canada, Quebec

Europe

Spain

Australia, Victoria




Posts Archive